Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
Posted by Michael Wonder on 17 Aug 2023
Keytruda backed for 'basket' of new cancers via NHS
17 August 2023 - The UK's cost effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of ...
Posted by Michael Wonder on 01 Aug 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia
1 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jul 2023
Talazoparib tosylate for the treatment of patients with advanced, germline BRCA mutation positive, HER2 negative breast cancer
28 July 2023 - NICE has published preliminary evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment of ...
Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, ...
Posted by Michael Wonder on 12 Jul 2023
Lorlatinib for the treatment of adults with advanced ALK positive non-small-cell lung cancer
12 July 2023 - NICE has published final evidence-based recommendations on the use of lorlatinib (Lorviqua) for the treatment of ...
Posted by Michael Wonder on 05 Jul 2023
Olaparib for the maintenance treatment of adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after two or more courses of platinum-based chemotherapy
5 July 2023 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the maintenance treatment ...
Posted by Michael Wonder on 27 Jun 2023
Olaparib in combination with bevacizumab for the maintenance treatment of adults with advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
27 June 2023 - The Department of Health and Social Care has asked the NICE to review its guidance on ...
Posted by Michael Wonder on 21 Jun 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with lenvatinib ...
Posted by Michael Wonder on 21 Jun 2023
Darolutamide in combination with androgen deprivation therapy and docetaxel for the treatment of patients with hormone-sensitive metastatic prostate cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of darolutamide (Nubeqa) in combination with androgen ...
Posted by Michael Wonder on 20 Jun 2023
Cemiplimab for the treatment of patients with recurrent or metastatic cervical cancer
20 June 2023 - NICE is unable to make a recommendation on the use of cemiplimab (Libtayo) for the treatment of ...
Posted by Michael Wonder on 14 Jun 2023
Dabrafenib mesylate and trametinib dimethyl sulphoxide for the treatment of patients with advanced BRAF V600 mutation positive non-small-cell lung cancer
14 June 2023 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Tafinlar) and trametinib dimethyl ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
7 June 2023 - NICE has published final evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
7 June 2023 - NICE has published final evidence-based recommendations on the use of brexucabtagene autoleucel (Tecartus) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma
7 June 2023 - NICE has published evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment of ...